Physician

Lynsay Leighanne Brautnick, M.D.

According to 2025 Medicare claims, Lynsay Brautnick, M.D. (NPI: 1548317340) practices medical oncology in the Fayetteville-Springdale-Rogers, AR market, with the plurality of this provider's patient population coming from Benton, AR. This provider's primary affiliated billing organization is HIGHLANDS ONCOLOGY GROUP PA (NPI: 1346211323; TIN: 710788742) and primary practice location at 72758-8602. Brautnick is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616), participating under the MSSP model.

Brautnick's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,344 traditional Medicare patients, billed 216,284 HCPCS/CPT codes, and received $3,728,074 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,838 prescription claims across 343 beneficiaries totaling $3,578,132 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 207 claims. Open Payments data shows 64 records totaling $884. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $831,670 to $3,578,132. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $15,144 to $4,283.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,271	245,289	$2,879,871
2016	1,356	365,881	$3,705,847
2017	1,386	363,607	$4,388,024
2018	1,465	361,668	$5,037,558
2019	1,584	436,941	$5,109,348
2020	1,517	360,217	$5,343,423
2021	1,579	334,000	$4,599,240
2022	1,432	275,178	$4,175,167
2023	1,265	233,939	$3,549,236
2024	1,344	216,284	$3,728,074

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	356	1,643	$831,670
2016	413	1,904	$988,250
2017	373	1,752	$1,078,627
2018	395	1,852	$1,583,840
2019	538	2,371	$2,695,341
2020	573	2,246	$2,973,166
2021	433	2,172	$2,013,957
2022	389	1,906	$1,699,736
2023	384	1,626	$2,268,532
2024	343	1,838	$3,578,132

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	274	$52,481
2016	N/R	206	$46,280
2017	N/R	80	$11,688
2018	N/R	134	$10,888
2019	11	89	$9,975
2020	24	125	$8,623
2021	30	137	$8,489
2022	25	182	$6,506
2023	49	289	$46,485
2024	39	207	$10,362

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	719	1,742	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	780	2,063	$8
83735	Magnesium level	704	1,709	$7
83615	Lactate dehydrogenase (enzyme) level	701	1,703	$6
84100	Phosphate level	701	1,705	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	51	1,530	$845,531
Cabometyx	Cabozantinib S-Malate	21	608	$419,728
Fruzaqla	Fruquintinib	13	350	$292,123
Stivarga	Regorafenib	15	399	$213,819
Pomalyst	Pomalidomide	14	392	$182,266

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4407	Ostomy skin barrier, with flange (solid, flexible, or accordion), extended wear, with built-in convexity, 4 x 4 inches or smaller, each	N	N/R	11	$2,998
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	21	$1,977
J8521	Capecitabine, oral, 500 mg	N	12	41	$1,700
A4419	Ostomy pouch, closed; for use on barrier with non-locking flange, with filter (2 piece), each	N	N/R	12	$1,326
J8999	Prescription drug, oral, chemotherapeutic, nos	N	N/R	25	$863

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	64	$884	Ipsen Biopharmaceuticals, Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lynsay Leighanne Brautnick, M.D.?

Tedicare shows public-source Medicare data for Lynsay Leighanne Brautnick, M.D. (NPI 1548317340), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lynsay Leighanne Brautnick, M.D. have ACO affiliation data?

Lynsay Leighanne Brautnick, M.D. is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616).

What billing organization is linked to Lynsay Leighanne Brautnick, M.D.?

Lynsay Leighanne Brautnick, M.D. is linked to HIGHLANDS ONCOLOGY GROUP PA (billing NPI 1346211323) in the available physician profile data.

Does Lynsay Leighanne Brautnick, M.D. have Open Payments data?

Lynsay Leighanne Brautnick, M.D. has 64 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.